You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
TOKYO, April 24, 2026 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that MSN Pharmaceuticals, Inc. and MSN Laboratories Private Ltd....
Read more about Astellas Amends Settlement and License Agreement with MSN regarding Myrbetriq®
- Submission based on statistically significant event-free and overall survival data from the Phase 3 EV-304 trial - - Building on the existing indication in cisplatin-ineligible muscle-invasive...
- Setidegrasib is an investigational, novel KRAS G12D-targeted protein degrader - - KRAS G12D mutations occur in approximately 40% of pancreatic ductal adenocarcinomas, with no approved targeted...
TOKYO, March 31, 2026 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that the following changes to its Top Management, effective April 1, 2026.
Read more about Astellas Announces Top Management Personnel Change
TOKYO, March 23, 2026 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that the European Medicines Agency (EMA) has validated for review a...
Follow us
